| Followers | 236 |
| Posts | 10817 |
| Boards Moderated | 0 |
| Alias Born | 07/17/2006 |
Monday, August 22, 2016 6:23:52 PM
KIWI...
The annual event rate in the JELIS placebo arm was 2.3%...Look it up..
Much ado is directed to the "angina" effect...A couple of points here..First of all as far as CVD events in JELIS..Angina was not considered an event...Only unstable angina was deemed a CVD event..
Unstable angina falls under the ACS (acute coronary synrdrome) definition. Unstable angina is very serious...
http://www.aafp.org/afp/2009/0815/p383.html
So its not..."Oh its only unstable angina".
As a matter of fact in JELIS the incidence of unstable angina was twice as high as fatal and non fatal heart attacks...Not like there was a ten to one ratio..
As far as your 2903 patients having angina, that was not their sole affliction..Two thirds of those had other conditions such as previous MIs, or previous coronary surgery...There's going to be a lot of folks with angina (and other conditions in R-I, you want to break out your angina argument for R-I guys too) seems like the risk is well matched.
Please don't try to blow smoke in my direction...
":>) JL
The annual event rate in the JELIS placebo arm was 2.3%...Look it up..
Much ado is directed to the "angina" effect...A couple of points here..First of all as far as CVD events in JELIS..Angina was not considered an event...Only unstable angina was deemed a CVD event..
Unstable angina falls under the ACS (acute coronary synrdrome) definition. Unstable angina is very serious...
http://www.aafp.org/afp/2009/0815/p383.html
So its not..."Oh its only unstable angina".
As a matter of fact in JELIS the incidence of unstable angina was twice as high as fatal and non fatal heart attacks...Not like there was a ten to one ratio..
As far as your 2903 patients having angina, that was not their sole affliction..Two thirds of those had other conditions such as previous MIs, or previous coronary surgery...There's going to be a lot of folks with angina (and other conditions in R-I, you want to break out your angina argument for R-I guys too) seems like the risk is well matched.
Please don't try to blow smoke in my direction...
":>) JL
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
